Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.

NCT07763821 | Not Yet Recruiting

• 1 other identifier: Serum Ribonuclease 1 in SLE
• Study Type: observational
• Target: 128
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.

Conditions

System Lupus Erythematosus(SLE)

Keywords

ribonuclease 1, lupus nephritis

Outcome Measures

Primary Outcomes (1)

• Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.

  Ribonuclease 1 (RNASE1) is a secreted endoribonuclease predominantly produced by endothelial cells and plays an essential role in the degradation of extracellular RNA \[11\]. These are suggested to promote endothelial activation, immune cell infiltration and activation, so promote inflammatory responses \[12-15\]. Since that endothelial dysfunction \& inflammatory signalling are central mechanism in LN pathogenesis, dysregulation of RNASE1 mediated extracellular RNA clearance may contribute to renal inflammatory injury, suggesting RNASE1 as a potential biomarker in LN

  1 year

Study Arms (2)

lupus nephritis

lupus nephritis serum riboneuclease 1

lupus patients without nephritis

lupus patients without nephritis serum riboneuclease 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Systemic lupus patients from rheumatology outpatient clinic assuit university

You may qualify if:

• Adult patients (≥18 years old) with non lupus nephritis SLE diagnosed according to the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus .
• Adult patients (≥18 years old) with Lupus Nephritis classified according to the 2018 ISN/RPS classification criteria.

You may not qualify if:

• Patients less than 18 years old
• Patients with other autoimmune diseases
• Active infection and malignancy
• Pregnancy and lactation
• Inability to provide informed consent

Sponsors & Collaborators

• Assiut University: lead

Related Publications (6)

• Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39.

  PMID: 27306639 BACKGROUND

• Singh S, Saxena R. Lupus nephritis. Am J Med Sci. 2009 Jun;337(6):451-60. doi: 10.1097/MAJ.0b013e3181907b3d.

  PMID: 19390431 BACKGROUND

• Pons-Estel GJ, Serrano R, Plasin MA, Espinosa G, Cervera R. Epidemiology and management of refractory lupus nephritis. Autoimmun Rev. 2011 Sep;10(11):655-63. doi: 10.1016/j.autrev.2011.04.032. Epub 2011 May 1.

  PMID: 21565286 BACKGROUND

• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308. doi: 10.1097/01.md.0000091181.93122.55.

  PMID: 14530779 BACKGROUND

• Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011 Aug;50(8):1424-30. doi: 10.1093/rheumatology/ker101. Epub 2011 Mar 16.

  PMID: 21415024 BACKGROUND

• Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. doi: 10.1002/art.21955.

  PMID: 16868977 BACKGROUND

MeSH Terms

Conditions

Lupus Erythematosus, Systemic; Lupus Nephritis

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Marwa Ahmad Abdelaziz, Associate Professor

  Marwa.a.galal@aun.edu.eg

  STUDY DIRECTOR

• Gehan Ibrahim Salem, Professor

  gehan_us@yahoo.com

  STUDY DIRECTOR

• Ahmed Abdelkhalk Ibrahim, Lecturer

  ahmedhafez_1122@yahoo.com

  STUDY DIRECTOR

• Amira Mohammad Mansour, Assistant Lecturer

  am9322729@gmail.com

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amira Mohammad Mansour, Assistant lecturer

CONTACT

0201099777532; am9322729@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant lecturer

Study Record Dates

• First Submitted: August 9, 2026
• First Posted: August 13, 2026
• Study Start (Estimated): September 30, 2026
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): December 1, 2028
• Last Updated: August 13, 2026

Record last verified: 2026-08